Fig. 8
From: New opportunities for RGD-engineered metal nanoparticles in cancer
Planar γ images of c(RGDfK)@(Or)3-CGG/99mTc): (a) a normal mouse, (b) a U87MG tumor-bearing mouse (c) a blocked tumor bearing mouse (U87MG onto the left front flank) after co-administration of an excess amount of the non-radiolabeled RGD derivative at 60 min p.i. The arrows indicate the presence of the tumor (or blocked tumor), kidneys, bladder and injection point. Reproduced with permission from ref [190]